intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months. "This is a deadly disease with very ...

Adding IP chemotherapy to intravenous chemotherapy produces significantly longer progression-free and overall survival in ovarian cancer patients with small tumors (<1 cm). Toxicities of IP ...

A new treatment for colorectal cancer that has spread to the liver is showing promising results in Dutch medical trials. The ...

Researchers have found in a randomised trial that High-dose IV vitamin C combined with standard chemotherapy significantly ...

At present, most chemotherapy drug treatments against cancer are delivered by an intravenous drip over several hours on a hospital ward. Patients normally have to make daily trips for a week at a ...

GREENFIELD — Sue Ann Wortman Cancer Center is doubling the size of its infusion center, where patients receive chemotherapy ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Surgery and standard intravenous chemotherapy with a platinum-taxane combination induces complete remission in the majority of patients with newly diagnosed ovarian cancer. Most patients will ...

Mayo Clinic, Mount Sinai and Huntsman Cancer Insitute are delivering services from chemotherapy to imaging in cancer patients ...

Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a second-line therapy.

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.